Skip to content

Enhancement of Learning Associated Neural Plasticity by Selective Serotonin Reuptake Inhibitors

Enhancement of Learning Associated Neural Plasticity by Selective Serotonin Reuptake Inhibitors

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02753738
Enrollment
80
Registered
2016-04-28
Start date
2016-08-31
Completion date
Unknown
Last updated
2016-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuronal Plasticity, Ssri

Brief summary

Background: Conclusive evidence states that the serotonergic system mediates neuroplasticity from early embryonic development until brain maturation in adulthood. This study aims to demonstrate that selective serotonin reuptake inhibitors (SSRIs) enhance learning-dependent neuroplasticity in vivo, hereby contributing to the investigators understanding of the mechanism of action of therapy with SSRIs. Objectives: 1. To prove a positive influence of SSRIs on structural remodeling during learning, reflected by enhancements of gray and white matter microstructure, connectivity and functionality in brain regions involved in learning processes. 2. To show that this effect is topologically specific, i.e. that enhancements of plasticity markers are found in different regions depending on their involvement during the performance of specific learning tasks. Study design: Randomized, double-blind, placebo-controlled, longitudinal mono-center study. 80 healthy subjects will undergo three MRI scanning sessions: 1. baseline, at study entry, 2. after 3 weeks of facial/emotional (n=40) or Chinese character-meaning learning (n=40) and 3. after 3 weeks learning of new associations under administration of an SSRI or placebo. Methods: MRI measurements will be performed on a 3 Tesla PRISMA MAGNETOM MR scanner. Changes in gray matter microstructure will be assessed using high-resolution structural MRI and analyzed with voxel-based morphometry (VBM). Diffusion tensor imaging (DTI) enables non-invasive investigation of neuroplasticity in the human brain based on the reduction in mean diffusivity associated with swelling of astrocytes after increased synaptic activity. Resting-state functional MRI (fMRI) will allow for the measurement of changes in functional coupling between brain regions, and fMRI during tasks will assess differential activity in brain regions during learning. Relevance and implications: This study aims to provide evidence that SSRIs facilitate cytoarchitectonical restructuring. In addition to expanding the investigators current knowledge on the trophic effects of SSRIs, the results of this study will also elucidate interactions between the serotonergic system and changes to neuronal networks during learning as well as their behavioral consequences. By probing the neurobiological correlates of the antidepressant and anti-anxiety effects of SSRIs, this study will provide a rationale for targeted interventions that harness the neuroplasticity enhancing properties of SSRIs to facilitate therapeutic processes.

Interventions

DRUGEscitalopram

Tablet 10mg, 21 days

DRUGPlacebo

Tablet, 21 days

OTHER3xMR scan (fMRI, DTI, strucutral MRI)

3 Tesla PRISMA MAGNETOM MR scanner; performed at baseline, after 21 days of performing learning paradigms and after 21 days of drug/placebo treatment and re-learning paradigms

BEHAVIORALAssociation learning paradigm

21 daily internet-based sessions (20min) of learning associations (pairs) of stimuli

BEHAVIORALAssociation re-learning paradigm

21 daily internet-based sessions (20min) of learning new associations (pairs) of stimuli performed during escitalopram/placebo treatment

Sponsors

Medical University of Vienna
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* General health based on medical history, physical examination and structured clinical interview for DSM-IV (SCID) * Willingness and competence to sign the informed consent form * Right-handedness * Non-smoker, and non-alcohol drinker

Exclusion criteria

* Any medical, psychiatric or neurological illness * Current or former substance abuse * Any implant or stainless steel graft or any other contraindications for MRI * First degree relatives with a history of psychiatric illness or substance abuse * Color blindness, any Chinese language skills * Failure to comply with the study protocol or to follow the instructions of the investigating team * Lifetime use of SSRIs or related psychotropic agents * Non-Caucasian

Design outcomes

Primary

MeasureTime frameDescription
Gray matter volume21 daysvoxel based morphometry (T1 weighted MPRAGE sequence)
Mean diffusivity21 daysdiffusion tensor imaging

Secondary

MeasureTime frameDescription
BOLD signal21 daysfunctional MRI (learning paradigms)

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026